Literature DB >> 24081481

Immunoglobulin injection for the treatment of multiple oral ulcers in Stevens-Johnson syndrome.

M Cicciù1, F Chiera, R Gallizzi, A Cicciù, C D Salpietro.   

Abstract

BACKGROUND: Stevens-Johnson syndrome (SJS) is a rare genetic disorder. The syndrome presents with severe purulent conjunctivitis, stomatitis with mucosal necrosis, and purpuric macules. This syndrome is associated with hypersensitive reaction usually stimulated by infection, vaccination, systemic diseases, physical agents, foods or drugs. However, only few cases reported can be related to infectious agents, but the causative role of infectious microorganisms seems relevant in paediatric patients. Authors want to underline the positive response of a new way of therapy by immunoglobulin injection. CASE REPORT: This case describes a 10-year-old girl with several erosions disseminated in the oral cavity mucosa. The girl had skin erosions that led to the clinical diagnosis of SJS. The past medical history of the patient revealed that those symptoms occured every 6 months over the last 2 years with 2 consecutive weeks of acute manifestations. At that moment, the paediatrician decided for cortisone administration in order to manage the acute symptoms, but after 6 months a new acute episode was observed. For this reason the patient was referred to the Department of Genetics and Immunological Paediatrics. TREATMENT: Oral ulcers had been topically treated with an oral balance gel. Intravenous injection of immunoglobulin was then applied and the patient was discharged after 5 days of treatment with the total symptoms in remission. FOLLOW-UP: The patient was followed up 3 monthly over the next 24 months. At that time no relapse of the SJS was observed.
CONCLUSION: The seriousness of this condition imposes a prompt recognition. Paediatric dentists should recognise the clinical signs of possible SJS as soon as possible in order to perform a quick diagnosis and initiate treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24081481     DOI: 10.1007/s40368-013-0086-8

Source DB:  PubMed          Journal:  Eur Arch Paediatr Dent        ISSN: 1818-6300


  6 in total

Review 1.  Toxic epidermal necrolysis.

Authors:  Frederick A Pereira; Adarsh Vijay Mudgil; David M Rosmarin
Journal:  J Am Acad Dermatol       Date:  2007-02       Impact factor: 11.527

Review 2.  Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.

Authors:  Scott Worswick; Jonathan Cotliar
Journal:  Dermatol Ther       Date:  2011 Mar-Apr       Impact factor: 2.851

3.  Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report.

Authors:  M Lissia; A Figus; C Rubino
Journal:  Br J Plast Surg       Date:  2005-06

Review 4.  Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature.

Authors:  Erik Letko; Dean N Papaliodis; George N Papaliodis; Yassine J Daoud; A Razzaque Ahmed; C Stephen Foster
Journal:  Ann Allergy Asthma Immunol       Date:  2005-04       Impact factor: 6.347

Review 5.  An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children.

Authors:  Mark Jean-Aan Koh; Yong-Kwang Tay
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

6.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

Authors:  S Bastuji-Garin; B Rzany; R S Stern; N H Shear; L Naldi; J C Roujeau
Journal:  Arch Dermatol       Date:  1993-01
  6 in total
  1 in total

Review 1.  Diabetes: Oral Health Related Quality of Life and Oral Alterations.

Authors:  Gabriele Cervino; Antonella Terranova; Francesco Briguglio; Rosa De Stefano; Fausto Famà; Cesare D'Amico; Giulia Amoroso; Stefania Marino; Francesca Gorassini; Roberta Mastroieni; Cristina Scoglio; Francesco Catalano; Floriana Lauritano; Marco Matarese; Roberto Lo Giudice; Enrico Nastro Siniscalchi; Luca Fiorillo
Journal:  Biomed Res Int       Date:  2019-03-18       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.